Asabys, partner of Catalonia.health, has led a $10.5 million (€9.4 million) seed funding round for ALLOX, a Barcelona-based biotechnology company that combines high-throughput genetics, experimental biology and artificial intelligence to discover new allosteric sites in proteins.
The round was carried out through the Sabadell Asabys II fund, with participation from CDTI (through SICC Innvierte) and the Catalan Finance Institute (ICF).
The funds will be used to expand ALLOX’s platform, develop proprietary AI models and advance a pipeline of small molecules targeting protein–protein interactions and transcription factors, therapeutic targets that have historically been difficult to address with drugs. The company also plans to foster strategic collaborations with pharmaceutical and biotechnology companies.
ALLOX strengthens its board of directors
Alongside the closing of the funding round, the company has appointed Morten Graugaard, co-founder and Chief Business Officer (CBO) of Orbis Medicines and former partner at Novo Holdings, as independent chair of the board of directors.
Clara Campàs, co-founder and managing partner of Asabys Partners, highlighted the potential of ALLOX’s platform to broaden the range of biological processes that can be targeted with drugs. She also noted that Graugaard’s appointment strengthens the company’s execution capabilities and corporate governance.
© Catalonia.health, 2026
Comments